Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Cosela (trilaciclib) is given before chemotherapy to protect bone marrow function.
November is Lung Cancer Awareness Month.
The premier platform not only for the presentation of new science, but also for unique networking opportunities.
Here are latest arrivals approved by the Food and Drug Administration.
Scientists discover a single gene’s role in drug resistance and look for ways to re-sensitize tumors to chemotherapy.
Lurbinectedin shrank tumors in a third of people with this less common type of lung cancer.
Additions of the checkpoint inhibitor led to improved survival compared with chemotherapy alone.
Although the improvement in survival with immunotherapy was modest, it is noteworthy because SCLC has been such a recalcitrant disease.
New immunotherapy option approved for uncommon, aggressive type of lung cancer.
A Phase II trial reached its primary endpoint of overall response in just over a third of participants.
Progression-free and overall survival improved in patients treated with Tecentriq plus chemotherapy.
Because so few people diagnosed with SCLC survive for even a year despite treatment, an advance in survival rate is quite significant.
Responses were durable for at least six months in 77% of responders.
First new treatment in two decades for uncommon type of lung cancer.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.